Heng Li
- Molecular Biology top 10%
- Cancer Research top 2%
- Pulmonary and Respiratory Medicine top 10%
- Surgery top 10%
- Oncology
- Topics
- Renal cell carcinoma treatment (13 papers)MicroRNA in disease regulation (10 papers)Cancer-related molecular mechanisms research (10 papers)
- Journals
- PLoS ONEOncogeneScientific Reports
- Partner nations
- ChinaUnited StatesMacao
In The Last Decade
Heng Li
77 papers receiving 2.0k citations
Peers
Comparison fields: 5 of 116
- Molecular Biology 1.2k
- Cancer Research 936
- Pulmonary and Respiratory Medicine 315
- Surgery 284
- Oncology 185
Countries citing papers authored by Heng Li
This map shows the geographic impact of Heng Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heng Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heng Li more than expected).
Fields of papers citing papers by Heng Li
This network shows the impact of papers produced by Heng Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heng Li. The network helps show where Heng Li may publish in the future.
Co-authorship network of co-authors of Heng Li
This figure shows the co-authorship network connecting the top 25 collaborators of Heng Li. A scholar is included among the top collaborators of Heng Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heng Li. Heng Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 1 | |
| 3 | 0 | |
| 4 | 1 | |
| 5 | 6 | |
| 6 | 3 | |
| 7 | 3 | |
| 8 | 9 | |
| 9 | 7 | |
| 10 | 7 | |
| 11 | 5 | |
| 12 | 23 | |
| 13 | 76 | |
| 14 | 17 | |
| 15 | 9 | |
| 16 | 9 | |
| 17 | 56 | |
| 18 | 166 | |
| 19 | 92 | |
| 20 | The credit risk of factoring service for commercial banks in our country and its countermeasures | 0 |
About Heng Li
Heng Li is a scholar working on Cancer Research, Urology and Pulmonary and Respiratory Medicine, having authored 91 papers that have together received 2.0k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (13 papers), MicroRNA in disease regulation (10 papers) and Cancer-related molecular mechanisms research (10 papers). The work is most often cited by research in Cancer Research (936 citations), Urology (115 citations) and Molecular Biology (1.2k citations). Heng Li has collaborated with scholars based in China, United States and Macao. Frequent co-authors include Hua Xu, Zhangqun Ye, Yu Gan, Wei Xiao, Haibing Xiao, Kun Tang, Weimin Yao, Ke Chen, Bin Lang and Wei Guan. Their work appears in journals such as PLoS ONE, Oncogene and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.